Clinical trial
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's…
NCT00053027 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00053027 |
|---|---|
| Title | Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma |
| Official title | Phase II Trial of Rituximab and 2-Chlorodeoxyadenosine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL) |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cladribine |
| Enrollment | 30 |
| Start date | Feb 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Nov 1, 2009 |
| First posted | Jan 28, 2003 |
| Last update posted | Dec 7, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: